Trial Information

Summary: Bothered by arthritis? Concerned about heart disease?

Learn about a new research study especially for patients with arthritis who have or are at risk for heart disease.

This study will compare 3 approved medicines commonly used to treat pain - Celecoxib, Ibuprofen, and Naproxen.

Study Participants Must:

  • Be 18 years of age or older
  • Have had OA or RA and be on regular medication for the pain for at least 6 months.
  • Have or be at high risk for heart disease (for example, if you’ve had a heart attack, stroke, or have diabetes). Your doctor can tell you if you are at high risk for heart disease.

Study Participants May Receive:

  • Study medication
  • Study-related physical exams and laboratory tests
  • Compensation for time and travel

For more information,

Contact:

Tania Torres, CMA, Recruitment Specialist
Genesis Research International
280 Wekiva Springs Road
Suite 1030
Orlando - Longwood, FL 32779
Telephone: 407-331-9505
Fax: 407-331-0191
Email:

Profile Page: Genesis Research International, Orlando - Longwood, FL

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:


Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:29:58 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA